# A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

> **NCT03980314** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 261 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03980314
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2021-03-04
- **Final completion:** 2023-11-06
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980314, "A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03980314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*